Sionna Therapeutics is trading 8.6% down at $3.41 amid a sharp market sell-off and weakness across biotech.
- No new company-specific announcement explaining the November 5 decline was identified; its latest release announced upcoming investor conferences.
- The supplied sector context reports XBI down 5.19%.
- Reuters reported a broad risk-off decline as investors reassessed AI spending and potential scrutiny of data-center expansion.